Streetbeat News

Analyst Ratings

VIR

JP Morgan has downgraded Vir Biotechnology (NASDAQ:VIR) from its previous rating to Neutral, significantly reducing the price target from $23.00 to $9.00. Following this news, Vir Biotechnology's shares have fallen by 6.18% to $8.96. The new price target suggests a marginal increase of 0.45% from the current share price. Vir Biotechnology is a commercial-stage immunology company with a focus on infectious diseases and has multiple technology platforms and product candidates targeting various diseases.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 5:00 pm

FHB

Wells Fargo has maintained its Underweight rating for First Hawaiian (NASDAQ:FHB) but raised its price target from $18.00 to $20.00. Despite the increase in the price target, the new target still suggests a potential downside of 10.27% from the current share price of $22.29. First Hawaiian is a bank holding company offering a range of banking services, with key revenue derived from Retail Banking.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 5:00 pm

AMGN

Amgen (NASDAQ:AMGN) has received mixed ratings from 11 analysts, with an average 12-month price target of $291.91, indicating a 5.6% increase from the previous target. Recent actions include ratings adjustments and price target changes by analysts from UBS, Daiwa Capital, BMO Capital, RBC Capital, Truist Securities, Deutsche Bank, and Morgan Stanley. Amgen's financials show a market cap above industry average, a 3.77% revenue growth, a high net margin of 25.06%, an ROE of 23.97%, and an ROA of 1.91%, but a high debt-to-equity ratio of 7.9. The company's portfolio includes drugs like Epogen, Aranesp, Neupogen, Neulasta, Enbrel, Otezla, Vectibix, Prolia/Xgeva, Evenity, Repatha, Aimovig, Lumakras, Tezspire, and Kyprolis from the Onyx acquisition. The recent Horizon acquisition adds drugs for rare diseases, including Tepezza.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 5:00 pm

CHH

Barclays has maintained its Underweight rating on Choice Hotels Intl (NYSE:CHH) but raised its price target from $112.00 to $114.00. Despite the increase in the price target, the new target still suggests a potential downside of 6.22% from the current share price of $121.56. Choice Hotels operates 628,000 rooms across 13 brands and franchises make up 99% of its revenue. The United States accounts for 79% of total rooms. The company recently added the Everhome brand and closed on its Radisson acquisition, adding approximately 70,000 rooms.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 5:00 pm

CLFD

Roth MKM has maintained its Buy rating for Clearfield (NASDAQ:CLFD) but reduced its price target from $49.00 to $47.00. Clearfield's shares are currently trading at $25.56, and the new price target suggests a potential upside of 83.88%. Clearfield designs, manufactures, and distributes fiber optic management products and has a global presence, with most revenue coming from the U.S.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 5:00 pm

INTC

Goldman Sachs has reaffirmed its Sell rating on Intel Corporation (NASDAQ:INTC) but increased its price target from $34.00 to $39.00. Despite the raised target, the new price still suggests a potential downside of 9.9% from Intel's current share price of $43.28. Intel is a major chipmaker, leading in the PC and server CPU markets and expanding into new areas like automotive and IoT. The company is also moving towards an outsourced foundry model.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 5:00 pm

TMUS

T-Mobile US (NASDAQ:TMUS) has been reviewed by 11 analysts in the last three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $183.45, up from $175.86, with a high of $200.00 and a low of $168.00. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. T-Mobile US has shown solid revenue growth, a strong net margin, and efficient asset use, but a below-average return on equity. The company's debt-to-equity ratio is below the industry average, indicating a healthier balance sheet.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 5:00 pm

RJF

Morgan Stanley has maintained its Equal-Weight rating on Raymond James Financial (NYSE:RJF) and increased its price target from $106.00 to $113.00. RJF's shares are currently trading at $113.22, which is slightly above the new target. Raymond James Financial is a financial holding company with over $1.2 trillion in assets under administration as of September 2023, primarily in the U.S. and within its wealth-management segment.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 5:00 pm

TFII

RBC Capital analyst Walter Spracklin has reiterated an Outperform rating on TFI International (NYSE:TFII) and maintained a price target of $155. The reaffirmation of the positive outlook and price target suggests confidence in the company's performance and potential for stock appreciation.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 4:59 pm

OMI

UBS analyst Kevin Caliendo has maintained a Buy rating on Owens & Minor (NYSE:OMI) but has reduced the price target from $28 to $26.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 4:54 pm